Summary We have assessed the pharmacokinetics, pharmacological and anti-tumour effects of the specific steroidal anti-oestrogen ICI 182780 in 19 patients with advanced breast cancer resistant to tamoxifen. The agent was administered as a monthly depot intramuscular injection. Peak levels of ICI 182780 occurred a median of 8-9 days after dosing and then declined but were above the projected therapeutic threshold at day 28. Cmax during the first month was 10.5 ng/ml-' and during the sixth month was 12.6 ng ml-l. The AUCs were 140.5 and 206.8 ng day ml-' on the first and sixth month of dosing respectively, suggesting some drug accumulation. Luteinising hormone (LH) and follicle-stimulating hormone (FSH) levels rose after withdrawal of tamoxifen and then plateaued, suggesting no effect of ICI 182780 on the pituitary-hypothalamic axis. There were no significant changes in serum levels of prolactin, sex hormone-binding globulin (SHBG) or lipids. Sideeffects were infrequent. Hot-flushes and sweats were not induced and there was no apparent effect of treatment upon the endometrium or vagina. Thirteen (69%) patients responded (seven had partial responses and six showed 'no change' responses) to ICI 182780, after progression on tamoxifen, for a median duration of 25 months. Thus ICI 182780, given by monthly depot injection, and at the drug levels described, is an active second-line anti-oestrogen without apparent negative effects on the liver, brain or genital tract and warrants further evaluation in patients with advanced breast cancer.
Half of the patients with advanced breast cancer have tumours that either regress or remain stable when treated with tamoxifen. Despite initial response all such tumours eventually become resistant to this anti-oestrogen after a median duration of remission of about 18 months (Cole et al., 1971; Patterson et al., 1981) . Although it acts as an oestrogen antagonist with respect to the tumour, tamoxifen is oestrogenic with respect to bone (Turken et al., 1989) , the liver (Bertelli et al., 1988) and the endometrium (Fornander et al., 1989) . Potential causes of treatment failure may result from tamoxifen, or its metabolites (Osborne et al., 1991) becoming oestrogenic with respect to the tumour (Howell et al., 1990) or from tamoxifen becoming sequestered away from the oestrogen receptor (ER) and rendered inactive (Pavlick et al., 1992) .
A new class of specific anti-oestrogens has been developed that produce more complete suppression of the proliferative effects of oestrogen upon tumours. Substitution of a long side-chain at the 7 alpha position of the oestradiol molecule has produced compounds that appear more active as antioestrogens than the triphenylethylene derivatives such as tamoxifen (Wakeling and Bowler, 1987, 1988) . The structure of the prototype specific anti-oestrogen, ICI 164384, is shown in Figure 1 together with that of ICI 182780, {7a-[9(4,4,5,5,pentafluoropentyl-sulphinyl) nonyl]oestra-1 ,3,5,(10)-triene-3,17,B-diol} the compound selected for clinical evaluation because of its greater potency and affinity for the ER (Wakeling et al., 1991) .
Both compounds have been assessed using in vitro and animal models of human breast cancer and compared with non-steroidal, partial agonist anti-oestrogens, including tamoxifen, and also with oestrogen withdrawal. The specific anti-oestrogens have shown superiority over these alternative methods of oestrogen deprivation with respect to inhibition of cell proliferation and oestrogen-induced gene expression. ICI 164384 and ICI 182780 are up to two orders of magnitude more potent than tamoxifen as inhibitors of cell growth in vitro. (Wakeling and Bowler, 1987, 1988) and produce a more profound blockade of cell division in the GI phase of the cell cycle. The specific anti-oestrogens are more effective than tamoxifen in suppressing expression of oestrogen-induced genes, such as progesterone receptor (PgR), pS2 and cathepsin D (Nicholson et al., 1994) by breast cancer cells. The specific anti-oestrogens have also been shown to produce a rapid reduction of intracellular ER levels, possibly as a result of inhibition of ER dimerisation and reduction of the ER halflife (Fawell et al., 1990; Dauvois et al., 1992) . This latter effect is in contrast to that of tamoxifen, which has been shown to increase ER expression by breast cancer cells in vitro (Wakeling et al., 1989) .
The experiments outlined above were performed on cell lines but similar results were demonstrated when a shortacting, propylene glycol-based formulation of ICI 182780 was administered by daily intramuscular injection for 1 week before surgery to women with primary breast cancer. Compared with pretreatment tumour samples (obtained by Tru-cut biopsy), those obtained after treatment with the specific anti-oestrogen showed reduced proliferation (Ki67 expression) and reduced or absent expression of ER, PgR and pS2 (DeFriend et al., 1994b; Nicholson et al., 1994) . Similar clinical experiments with tamoxifen produced no change in ER expression, slightly increased PgR expression and a reduction in labelling index (Howell et al., 1988; Roberston et al., 1991; Clarke et al., 1993; Nicholson et al., 1994) . (Lykkesfeld and Sorenson, 1992; Brunner et al., 1993a,b; Lykkesfeld et al., 1994) or as xenografts in nude mice in vivo (Gottardis et al., 1989; Osborne et al., 1991) , the effects of ICI 182780 were evaluated in a group of post-menopausal patients with tamoxifen-resistant breast cancer. Since the partial agonist activity of tamoxifen on bone density and lipid levels has been reported to the beneficial in post-menopausal patients, the effects of ICI 182780 at other oestrogen target sites, including the hypothalamus/pituitary gland, the liver and the endometrium has also been assessed in this study.
We report that although some drug accumulation occurred at the dose level used in this study, administration of ICI 182780 was associated with a lower than expected incidence of side-effects (such as hot flushes and vaginal problems) together with a high response rate and long response duration in women previously treated with tamoxifen. A preliminary report of the early clinical result of this study has been published (Howell et al., 1995) .
Patients and methods Patients
Nineteen patients with advanced breast cancer resistant to tamoxifen were treated with ICI 182780. The study was approved by the ethics committees of each clinical centre. Patients were eligible for the study if they were postmenopausal and age less than 81 years, with histologically verified breast cancer. Patients were included if they had been treated with tamoxifen as an adjuvant to surgery for more than 2 years and then relapsed, or if they had been treated with tamoxifen for advanced disease, had a complete or partial remission or disease stabilisation ('no change') for at least 6 months, and subsequently progressed while taking tamoxifen. Patients were excluded if they had serious intercurrent disease, a WHO performance status of greater than 2, and a life expectancy of less than 3 months or had received previous cytotoxic chemotherapy for advanced breast cancer. The characteristics of the patients studied are summarised in Table I (Diamed, Switzerland) . Triglyceride levels were determined by the glyceryl phosphate oxidase-peroxidase-antiperoxidase method using a commercially available kit (Boehringer Mannheim, Germany). High-density lipoprotein (HDL) cholesterol levels were measured after pretreatment of the serum samples with buffered magnesium phosphotungstate, which selectively precipitates low-density lipoprotein (LDL) cholesterol, very low-density lipoprotein (VLDL) cholesterol and chylomicrons, leaving HDL cholesterol in the supernatant. Serum levels of LDL cholesterol were calculated using the Friedewald equation (Friedewald et al., 1972) .
Endometrial assessment
Endometrial thickness was measured in transverse section by transabdominal ultrasound using a Siemens Sonoline SL2 with a 3.5 MHz sector probe. Baseline and repeat scans at 3-6 monthly intervals were performed in five patients. Endometrial histology was reviewed on one patient who had a hysterectomy for uterine prolapse after 18 months on ICI 182780. Figure 2 . Comparison of data after the first and sixth monthly 250 mg doses of ICI 182780 showed that the mean exposure to the drug increased slightly after multiple dosing. Mean Cm,, (which occurred on day 7) increased from 10.5 ng ml-' to 12.8 ng ml-', accompanied by increases in mean end-of-month concentrations from 3.1 ng ml-' to 5.6 ng ml-' and AUC values from 140.5 ng day ml-' to 206.8 ng day ml-' for the first and sixth months respectively in the 11 patients studied. Multiple dosing produced a 1.2-fold increase in Cma,, and a 1.5-fold increase in AUC, indicating a degree of accumulation at the 250 mg dose level. This greater exposure was not associated with any increased side-effects or irritancy (see below). There was no significant difference in the median Cmax and AUC between responders and non-responders to treatment (Table  II) . After 6 months of treatment there was no significant difference between Cmax and AUC for patients who had a partial reponse (PR) compared with those with a no change (NC) response.
Effects on hormones and lipids The serum levels of FSH, LH, prolactin and SHBG, before and during treatment with ICI 182780, are shown in Figure  3 . The median levels of FSH and LH before starting treatment with ICI 182780 were below the normal range for post-menopausal women, whereas the median SHBG level was above the normal range, both possibly related to the agonist activity of previous treatment with tamoxifen. During the first 3 months of administration of ICI 182780, there was significant increases in the serum concentration of FSH (median pre-and post-treatment values 26 and 52 IU l-1 respectively; P<0.05, Wilcoxon's matched-pairs signed-rank test) and LH (median pre-and post-treatment values 26 and 42 IU 1-1 respectively; P<0.005). Thereafter, no further significant overall changes occurred in serum gonadotrophin levels but wide variation between individual patients were observed, reflected in the broad interquartile ranges seen in Figure 3 . Serum SHBG levels showed an overall trend to decrease following treatment with the specific anti-oestrogen, falling from a median level of 100 mmol 1-' pretreatment to 55 mmol 1-1 after 8 months of treatment (P= NS. Figure 3c ). formed in five responding patients. Endometrial thickness was greater than the expected < 2 mm usually found in postmenopausal women, in all patients. The thickness of the endometrium remained unchanged in all patients during treatment with ICI 182780 (Figure 4) (Wakeling, 1993) . In the present study, we have attempted to obtain preliminary data on the effects of long-term administration of ICI 182780 on the pituitary gland/hypothalamus, the liver and the endometrium. Serum gonadotrophin levels significantly increased during the first 3 months of treatment with ICI 182780 and then remained stable thereafter. This change is in contradistinction to that seen with the triphenylethylene antioestrogen, tamoxifen, which reduces serum levels of FSH and LH in post-menopausal patients because of its oestrogenic effect on the pituitary gland and hypothalamus (Willis et al., 1977) . All but four patients in the present study were treated with tamoxifen up until treatment with ICI 182780 was initiated. Levels of FSH and LH at this time were below the range for normal post-menopausal women, which is attributable to previous therapy with tamoxifen. The rise of gonadotrophins during the first 3 months of treatment with ICI 182780 may therefore have been a passive effect caused by cessation of tamoxifen rather than an active antioestrogen effect of the new agent. The fact that gonadotrophin levels rose to well within post-menopausal values and then remained stable would support the view that ICI 182780 is without effect on gonadotrophin levels. This apparent lack of activity of the specific anti-oestrogen on the hypothalamus and pituitary gland is further supported by the findings that ICI 182780 did not initiate or exacerbate hot flushes or sweats in the present study, nor did it produce significant changes in serum prolactin levels.
Treatment with tamoxifen has been reported to increase serum levels of SHBG secondary to a probable oestrogenic effect of tamoxifen on the liver (Sakai et al., 1978) . The levels of SHBG in some of our patients before starting therapy with ICI 182780 were high, consistent with the oestrogenic effect of prior treatment with tamoxifen. Following commencement of treatment with ICI 182780, a slight decline in SHBG levels occurred, consistent with tamoxifen withdrawal, but thereafter median levels of SHBG remained in the middle of the normal range for our laboratory, suggesting that the specific anti-oestrogen may have little effect on SHBG synthesis in the liver. A lack of effect of the compound on the liver is further suggested by evaluation of lipid changes. Tamoxifen is known to reduce levels of cholesterol and LDL cholesterol and is associated with an increase in triglycerides and HDL cholesterol consistent with an oestrogenic effect on the liver (Bertelli et al., 1988; Love et al. 1990 ). None of these changes reported during treatment with tamoxifen were observed during the present study. This would further suggest that ICI 182780 is peripherally selective with respect to the liver. However we cannot explain why there was not the expected changes in lipids as patients came off tamoxifen.
The lack of apparent adverse effects of ICI 182780 seen in the present study would, if confirmed in future larger trials, give the specific anti-oestrogen potential advantages over currently available second-line endocrine agents. The observed lack of effect of ICI 182780 on body weight over a period of study that ranged from 6 to 16 months would give the new agent a potential advantage over megestrol acetate, the most widely used second-line endocrine therapy in breast cancer, which resulted in weight gain of > 5% of body weight in 25% of patients in one study (Willemse et al., 1990 ) and a median weight gain of 9 lbs after 180 days of treatment in another (Cruz et al., 1990 (Lykkesfeldt and Sorenson, 1992) 
